Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-08

AUTHORS

Elizabeth A. Calhoun, Glen T. Schumock, June M. McKoy, Simon Pickard, Karen A. Fitzner, Elizabeth A. Heckinger, Eowyn F. Powell, Kathyrn R. McCaffrey, Charles L. Bennett

ABSTRACT

Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40–60%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature. More... »

PAGES

767-775

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003

DOI

http://dx.doi.org/10.2165/00019053-200523080-00003

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038420911

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16097839


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Attention Deficit Disorder with Hyperactivity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Small Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chicago", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Costs and Cost Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "England", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulocyte Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Midwestern United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calhoun", 
        "givenName": "Elizabeth A.", 
        "id": "sg:person.016654752007.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016654752007.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schumock", 
        "givenName": "Glen T.", 
        "id": "sg:person.01331114412.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331114412.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McKoy", 
        "givenName": "June M.", 
        "id": "sg:person.01330740160.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330740160.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pickard", 
        "givenName": "Simon", 
        "id": "sg:person.01152461067.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152461067.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fitzner", 
        "givenName": "Karen A.", 
        "id": "sg:person.01220574267.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220574267.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heckinger", 
        "givenName": "Elizabeth A.", 
        "id": "sg:person.0615632750.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615632750.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powell", 
        "givenName": "Eowyn F.", 
        "id": "sg:person.01335022667.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335022667.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCaffrey", 
        "givenName": "Kathyrn R.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bennett", 
        "givenName": "Charles L.", 
        "id": "sg:person.01100705232.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100705232.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00019053-199400062-00008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019047021", 
          "https://doi.org/10.2165/00019053-199400062-00008"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-08", 
    "datePublishedReg": "2005-08-01", 
    "description": "Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40\u201360%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00019053-200523080-00003", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "small cell lung cancer", 
      "granulocyte colony-stimulating factor", 
      "febrile neutropenia", 
      "cell lung cancer", 
      "primary prophylaxis", 
      "colony-stimulating factor", 
      "chemotherapeutic regimens", 
      "lung cancer", 
      "cancer patients", 
      "chemotherapy-associated febrile neutropenia", 
      "evidence-based clinical guidelines", 
      "FN rate", 
      "chemotherapy-induced neutropenia", 
      "productivity-related costs", 
      "use of filgrastim", 
      "severe febrile neutropenia", 
      "recombinant granulocyte colony-stimulating factor", 
      "future cost-effectiveness studies", 
      "cost-effectiveness ratio", 
      "healthcare payer perspective", 
      "cost-effectiveness studies", 
      "cost-effectiveness evidence", 
      "cost-effectiveness threshold", 
      "clinical guidelines", 
      "payer perspective", 
      "patients", 
      "prophylaxis", 
      "regimens", 
      "societal perspective", 
      "CSF", 
      "available evidence", 
      "pocket costs", 
      "indirect costs", 
      "neutropenia", 
      "risk threshold", 
      "American Society", 
      "cancer", 
      "same recommendations", 
      "pegfilgrastim", 
      "medications", 
      "filgrastim", 
      "ASCO", 
      "severity", 
      "evidence", 
      "rate", 
      "factors", 
      "CSFs", 
      "duration", 
      "use", 
      "guidelines", 
      "threshold", 
      "recommendations", 
      "half", 
      "study", 
      "benefits", 
      "people", 
      "literature", 
      "inclusion", 
      "ratio", 
      "importance", 
      "circumstances", 
      "cost", 
      "economic considerations", 
      "perspective", 
      "decisions", 
      "basis", 
      "consideration", 
      "current rules", 
      "society", 
      "range", 
      "economic benefits", 
      "rules", 
      "paper", 
      "Clinical Oncology (ASCO) evidence-based clinical guidelines", 
      "Oncology (ASCO) evidence-based clinical guidelines", 
      "available cost-effectiveness evidence", 
      "base-case rates"
    ], 
    "name": "Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer", 
    "pagination": "767-775", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038420911"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00019053-200523080-00003"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16097839"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00019053-200523080-00003", 
      "https://app.dimensions.ai/details/publication/pub.1038420911"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_397.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00019053-200523080-00003"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      22 PREDICATES      119 URIs      109 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00019053-200523080-00003 schema:about N08cd9bfe69fa42d49d8cd14ad760cedd
2 N15d2547a9ce44273b3684017703d8b8e
3 N202e746ffaa74038a6fabf0c2a000585
4 N6230ec03489e48d591a601ec74c4b25e
5 N7f4239b7ad34449e8c527610851c8217
6 N9c992c0f3ef0488382c87700149d12da
7 Naedfd7095b2c4bf3b6098f5f4dbdc3f7
8 Nb0616ef5022e49409506ddcb6a4926a7
9 Nb9f4ba734b6647ceafb25dad8b2312d2
10 Ncfe30f6830d04271a128e7a942c70018
11 Nec724589aa2243c99a4df105940a5db2
12 Nf412e5b99ff6439e9f4daddeafda05d0
13 Nf8b0dbbe52044fc9b27a7f66ff80e908
14 anzsrc-for:11
15 anzsrc-for:1112
16 anzsrc-for:1117
17 schema:author Nfb7e71418c80470596e903286bfe5053
18 schema:citation sg:pub.10.2165/00019053-199400062-00008
19 schema:datePublished 2005-08
20 schema:datePublishedReg 2005-08-01
21 schema:description Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40–60%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N10eb82873af048c7a72bd315576a55bf
26 N83a7310cb02a4719bb6901628d567c11
27 sg:journal.1102812
28 schema:keywords ASCO
29 American Society
30 CSF
31 CSFs
32 Clinical Oncology (ASCO) evidence-based clinical guidelines
33 FN rate
34 Oncology (ASCO) evidence-based clinical guidelines
35 available cost-effectiveness evidence
36 available evidence
37 base-case rates
38 basis
39 benefits
40 cancer
41 cancer patients
42 cell lung cancer
43 chemotherapeutic regimens
44 chemotherapy-associated febrile neutropenia
45 chemotherapy-induced neutropenia
46 circumstances
47 clinical guidelines
48 colony-stimulating factor
49 consideration
50 cost
51 cost-effectiveness evidence
52 cost-effectiveness ratio
53 cost-effectiveness studies
54 cost-effectiveness threshold
55 current rules
56 decisions
57 duration
58 economic benefits
59 economic considerations
60 evidence
61 evidence-based clinical guidelines
62 factors
63 febrile neutropenia
64 filgrastim
65 future cost-effectiveness studies
66 granulocyte colony-stimulating factor
67 guidelines
68 half
69 healthcare payer perspective
70 importance
71 inclusion
72 indirect costs
73 literature
74 lung cancer
75 medications
76 neutropenia
77 paper
78 patients
79 payer perspective
80 pegfilgrastim
81 people
82 perspective
83 pocket costs
84 primary prophylaxis
85 productivity-related costs
86 prophylaxis
87 range
88 rate
89 ratio
90 recombinant granulocyte colony-stimulating factor
91 recommendations
92 regimens
93 risk threshold
94 rules
95 same recommendations
96 severe febrile neutropenia
97 severity
98 small cell lung cancer
99 societal perspective
100 society
101 study
102 threshold
103 use
104 use of filgrastim
105 schema:name Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer
106 schema:pagination 767-775
107 schema:productId N6d1428a2e6424c0ba05c1d3e32ac4630
108 Na6ee6f561ebf45a1be6a4da53f966f23
109 Nab71d1fef7fa48d6a86d06bb95e64718
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038420911
111 https://doi.org/10.2165/00019053-200523080-00003
112 schema:sdDatePublished 2022-01-01T18:14
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher N32834d4d9c7b4a5a988cbfd21e4bac1c
115 schema:url https://doi.org/10.2165/00019053-200523080-00003
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N08cd9bfe69fa42d49d8cd14ad760cedd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Lung Neoplasms
121 rdf:type schema:DefinedTerm
122 N0d0e95968bcf46ed823122a0c3b71726 rdf:first sg:person.01220574267.85
123 rdf:rest N9ffb34218e93456ca10d3c69370a3fe1
124 N10eb82873af048c7a72bd315576a55bf schema:volumeNumber 23
125 rdf:type schema:PublicationVolume
126 N140235ddfc0447b69b828cf983e22ea8 rdf:first sg:person.01335022667.49
127 rdf:rest N22b15bb592ea4fdb97cd0de10fa2e334
128 N15d2547a9ce44273b3684017703d8b8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name England
130 rdf:type schema:DefinedTerm
131 N202e746ffaa74038a6fabf0c2a000585 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Recombinant Proteins
133 rdf:type schema:DefinedTerm
134 N22b15bb592ea4fdb97cd0de10fa2e334 rdf:first N31c5a8e7293a42caa541fb020369b148
135 rdf:rest Nf299487ae0b84d12a6969f1812905039
136 N31c5a8e7293a42caa541fb020369b148 schema:affiliation grid-institutes:grid.16753.36
137 schema:familyName McCaffrey
138 schema:givenName Kathyrn R.
139 rdf:type schema:Person
140 N32834d4d9c7b4a5a988cbfd21e4bac1c schema:name Springer Nature - SN SciGraph project
141 rdf:type schema:Organization
142 N6230ec03489e48d591a601ec74c4b25e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Attention Deficit Disorder with Hyperactivity
144 rdf:type schema:DefinedTerm
145 N6d1428a2e6424c0ba05c1d3e32ac4630 schema:name doi
146 schema:value 10.2165/00019053-200523080-00003
147 rdf:type schema:PropertyValue
148 N7c4a92420e7d479c8c6d7aadb901f934 rdf:first sg:person.01152461067.24
149 rdf:rest N0d0e95968bcf46ed823122a0c3b71726
150 N7f4239b7ad34449e8c527610851c8217 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Chicago
152 rdf:type schema:DefinedTerm
153 N83a7310cb02a4719bb6901628d567c11 schema:issueNumber 8
154 rdf:type schema:PublicationIssue
155 N8f45bb0c01034407bb687bcdd5244570 rdf:first sg:person.01330740160.15
156 rdf:rest N7c4a92420e7d479c8c6d7aadb901f934
157 N9c992c0f3ef0488382c87700149d12da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Neutropenia
159 rdf:type schema:DefinedTerm
160 N9ffb34218e93456ca10d3c69370a3fe1 rdf:first sg:person.0615632750.10
161 rdf:rest N140235ddfc0447b69b828cf983e22ea8
162 Na6ee6f561ebf45a1be6a4da53f966f23 schema:name pubmed_id
163 schema:value 16097839
164 rdf:type schema:PropertyValue
165 Nab71d1fef7fa48d6a86d06bb95e64718 schema:name dimensions_id
166 schema:value pub.1038420911
167 rdf:type schema:PropertyValue
168 Naedfd7095b2c4bf3b6098f5f4dbdc3f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Quality of Life
170 rdf:type schema:DefinedTerm
171 Nb0616ef5022e49409506ddcb6a4926a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Antineoplastic Agents
173 rdf:type schema:DefinedTerm
174 Nb9f4ba734b6647ceafb25dad8b2312d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 Ncfe30f6830d04271a128e7a942c70018 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Costs and Cost Analysis
179 rdf:type schema:DefinedTerm
180 Nd0babf3ae5b44a1487edc98f423a7603 rdf:first sg:person.01331114412.87
181 rdf:rest N8f45bb0c01034407bb687bcdd5244570
182 Nec724589aa2243c99a4df105940a5db2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Midwestern United States
184 rdf:type schema:DefinedTerm
185 Nf299487ae0b84d12a6969f1812905039 rdf:first sg:person.01100705232.37
186 rdf:rest rdf:nil
187 Nf412e5b99ff6439e9f4daddeafda05d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Carcinoma, Small Cell
189 rdf:type schema:DefinedTerm
190 Nf8b0dbbe52044fc9b27a7f66ff80e908 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Granulocyte Colony-Stimulating Factor
192 rdf:type schema:DefinedTerm
193 Nfb7e71418c80470596e903286bfe5053 rdf:first sg:person.016654752007.02
194 rdf:rest Nd0babf3ae5b44a1487edc98f423a7603
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
199 schema:name Oncology and Carcinogenesis
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
202 schema:name Public Health and Health Services
203 rdf:type schema:DefinedTerm
204 sg:journal.1102812 schema:issn 1170-7690
205 1179-2027
206 schema:name PharmacoEconomics
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.01100705232.37 schema:affiliation grid-institutes:grid.16753.36
210 schema:familyName Bennett
211 schema:givenName Charles L.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100705232.37
213 rdf:type schema:Person
214 sg:person.01152461067.24 schema:affiliation grid-institutes:grid.185648.6
215 schema:familyName Pickard
216 schema:givenName Simon
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152461067.24
218 rdf:type schema:Person
219 sg:person.01220574267.85 schema:affiliation grid-institutes:grid.16753.36
220 schema:familyName Fitzner
221 schema:givenName Karen A.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220574267.85
223 rdf:type schema:Person
224 sg:person.01330740160.15 schema:affiliation grid-institutes:grid.16753.36
225 schema:familyName McKoy
226 schema:givenName June M.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330740160.15
228 rdf:type schema:Person
229 sg:person.01331114412.87 schema:affiliation grid-institutes:grid.185648.6
230 schema:familyName Schumock
231 schema:givenName Glen T.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331114412.87
233 rdf:type schema:Person
234 sg:person.01335022667.49 schema:affiliation grid-institutes:grid.16753.36
235 schema:familyName Powell
236 schema:givenName Eowyn F.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335022667.49
238 rdf:type schema:Person
239 sg:person.016654752007.02 schema:affiliation grid-institutes:grid.185648.6
240 schema:familyName Calhoun
241 schema:givenName Elizabeth A.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016654752007.02
243 rdf:type schema:Person
244 sg:person.0615632750.10 schema:affiliation grid-institutes:grid.16753.36
245 schema:familyName Heckinger
246 schema:givenName Elizabeth A.
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615632750.10
248 rdf:type schema:Person
249 sg:pub.10.2165/00019053-199400062-00008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019047021
250 https://doi.org/10.2165/00019053-199400062-00008
251 rdf:type schema:CreativeWork
252 grid-institutes:grid.16753.36 schema:alternateName Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
253 schema:name Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
254 rdf:type schema:Organization
255 grid-institutes:grid.185648.6 schema:alternateName Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA
256 The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA
257 schema:name Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA
258 The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...